Skip to content
Bored Studies
RecruitingPhase 2

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Draig Therapeutics Ltd · NCT07610473

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
118
US sites recruiting
23
Study start
May 14, 2026
Record last updated
October 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Being studied: DT-101; Placebo

Conditions: Major Depressive Disorder (MDD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
  • Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
  • Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).

Exclusion Criteria

  • Pregnant or breastfeeding or plans to become pregnant during the study.
  • Unstable medical condition or unstable chronic disease.
  • Significant neurological abnormality.
  • History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
  • History of seizure.
  • In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Recruiting US locations

  • Draig Clinical Site

    Phoenix, AZ 85013

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Little Rock, AR 72211

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Bellflower, CA 90706

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Costa Mesa, CA 92626

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Lafayette, CA 94549

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Hialeah, FL 33016

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Orlando, FL 32803

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Orlando, FL 32807

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Tampa, FL 33607

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Tampa, FL 33613

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Decatur, GA 30030

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Chicago, IL 60610

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Skokie, IL 60076

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Boston, MA 02130

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    New York, NY 10025

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    New York, NY 10029

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Columbus, OH 43215

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Allentown, PA 18103

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Media, PA 19063

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    DeSoto, TX 75115

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Fort Worth, TX 76104

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Bellevue, WA 98007

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Seattle, WA 98104

    Site contact: Draig Clinical Site · +44(0)2920028450 · draig.aeron@seattlentc.com

Study contacts (from the official record)

  • Aeron-1 Clinical Team · +44(0)2920028450 · info@draigtherapeutics.com
All mental health studies in Arizona →
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive… (NCT07610473) | Bored Studies